Akimitsu Hirai

REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.

Okinawa Protein Tomography Ltd. provides polymeric molecular structure analysis services. Its technology allows imaging of macromolecules including proteins in multiple states at the single molecule-level by combining conventional electron tomography and a specifically designed 3D reconstruction program known as COMET. The firm analyzes data of molecular structures of protein samples. The company was founded by Akira Kamei on June 25, 2014 and is headquartered in Uruma, Japan.